Properties (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
clinical trial
|
| gptkbp:approves |
institutional review board
|
| gptkbp:built |
2021-12-31
|
| gptkbp:clinicalTrials |
NCT number
determined by statistical analysis |
| gptkbp:collaborations |
various research institutions
international research networks |
| gptkbp:collection |
patient-reported outcomes
|
| gptkbp:committee |
independent oversight
|
| gptkbp:community_involvement |
active drug and placebo
|
| gptkbp:community_service |
collected during the trial
evaluated for treatment response |
| gptkbp:complications |
monitored throughout the study
|
| gptkbp:condition |
Psoriasis
|
| gptkbp:contributedTo |
to dermatology field
|
| gptkbp:criteria |
adults with moderate to severe psoriasis
history of certain medical conditions |
| gptkbp:diseaseResistance |
measured by PASI score
|
| gptkbp:duration |
24 weeks
|
| gptkbp:enrollment |
diverse population
approximately 1000 participants |
| gptkbp:funding |
provided by sponsor
|
| gptkbp:future_plans |
Phase 3
|
| gptkbp:healthcare |
informed consent obtained
|
| https://www.w3.org/2000/01/rdf-schema#label |
DISCOVER-2
|
| gptkbp:impact |
12 weeks
assessed through questionnaires |
| gptkbp:is_a_site_for |
multiple locations
|
| gptkbp:is_studied_in |
completed
acknowledged in publications available for review. interventional study randomized, double-blind, placebo-controlled |
| gptkbp:launchDate |
2018-01-01
|
| gptkbp:leads |
gptkb:Dr._John_Doe
|
| gptkbp:location |
multiple countries
|
| gptkbp:notableWork |
discussed in final report
|
| gptkbp:outcome |
shared with stakeholders
Efficacy of treatment Safety of treatment improvement in psoriasis symptoms |
| gptkbp:priorityDate |
2020-12-31
|
| gptkbp:publications |
peer-reviewed articles
|
| gptkbp:recruitment |
through clinics and hospitals
|
| gptkbp:registration |
ClinicalTrials.gov
|
| gptkbp:regulatoryCompliance |
gptkb:FDA
made to health authorities |
| gptkbp:research |
impact on treatment guidelines
|
| gptkbp:result |
conferences and symposiums
published in medical journals |
| gptkbp:safety_features |
evaluated against standards
|
| gptkbp:safetyFeatures |
Bristol-Myers_Squibb's_drug
|
| gptkbp:sponsor |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:technique |
statistical analysis
double-blind computer-generated random numbers |
| gptkbp:technology |
suggested based on findings
|
| gptkbp:yearsActive |
assessed in subsequent studies
|